Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immutep Limited - American Depositary Shares (NQ:IMMP)

0.5440 +0.2292 (+72.81%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Immutep Limited - American Depositary Shares

< Previous 1 2 3 4 Next >
News headline image
IMMP Investor News: If You Have Suffered Losses in Immutep Ltd. (NASDAQ: IMMP), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
These stocks are moving in today's session ↗
Curious to know what's happening on the US markets one hour before the close of the markets on Wednesday? Join us as we explore the top gainers and losers in today's session. 
Via Chartmill
Topics Artificial Intelligence
News headline image
Which stocks are most active on Wednesday? ↗
These stocks are making the most noise in today's session. Stay tuned for the latest updates! 
Via Chartmill
Topics Artificial Intelligence
News headline image
Here are the top movers in Wednesday's session. ↗
Wondering how the US markets performed in the middle of the day on Wednesday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
Topics Artificial Intelligence
News headline image
These stocks are moving in today's pre-market session ↗
Before the US market kicks off on Wednesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
Topics Artificial Intelligence
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
From Pomerantz LLP
Via GlobeNewswire
News headline image
IMMP Investors Have Opportunity to Join Immutep Limited Fraud Investigation with the Schall Law Firm
From The Schall Law Firm
Via Business Wire
On Wednesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Immutep Limited - IMMP
From Pomerantz LLP
Via GlobeNewswire
News headline image
Rosen Law Firm Encourages Immutep Ltd. Investors to Inquire About Securities Class Action Investigation – IMMP
From Rosen Law Firm
Via Business Wire
On Tuesday, there are stocks with unusual volume. Let's take a look. ↗
Via Chartmill
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
SurgePays (NASDAQ: SURG) Expands Growth Strategy – New Lead-Driver to Boost Fintech Revenue – More Stocks Inside
Via AB Newswire
Topics Artificial Intelligence
News headline image
What's going on in today's session ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
There are notable gap-ups and gap-downs in today's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
From Immutep Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
Immutep Announces Update for TACTI-004 (KEYNOTE-F91) Phase III Trial in First Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
 
Via Benzinga
News headline image
Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo ↗
Immutep's efti combo with Keytruda and chemo shows a 60.8% response rate in lung cancer trial, with strong efficacy across PD-L1 expression levels. 
Via Benzinga
News headline image
Immutep’s Efti with KEYTRUDA® (pembrolizumab) & Chemotherapy Achieves High Response Rates in First-Line Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
News headline image
Unusual volume stocks in Wednesday's session ↗
Let's have a look at what is happening on the US markets on Wednesday. Below you can find the stocks with an unusual volume in today's session. 
Via Chartmill
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
In today's session, these stocks are experiencing unusual volume. 
Via Chartmill
News headline image
Ichor Holdings Posts Weak Earnings, Joins Fabrinet, Vertex Pharmaceuticals And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Immutep's Lead Cancer Drug Shows Promising 2-Year Survival Data In Lung Cancer Trial ↗
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, and chemotherapy. 
Via Benzinga
News headline image
Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer
From Immutep Limited
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.